Lv4
700 积分 2025-04-15 加入
Mapping the effectiveness and risks of GLP-1 receptor agonists
11天前
已完结
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
13天前
已关闭
Ecnoglutide, a biased GLP-1 receptor agonist as a potential new player for type 2 diabetes management?
1个月前
已完结
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
2个月前
已完结
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
2个月前
已完结
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
2个月前
已完结
Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects
2个月前
已完结
Is the steady-state concentration, duration of action, or molecular weight of GLP-1RA associated with cardiovascular and renal outcomes in type 2 diabetes?
2个月前
已完结
Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority, randomised, phase 3 trial
2个月前
已完结
Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
2个月前
已完结
皖公网安备34019202002308
